Loading
The standard chemotherapy recipes for bowel and pancreatic cancer, named from their ingredients: FOL (folinic acid) + F (5-fluorouracil) + OX (oxaliplatin), IRI (irinotecan), or both (FOLFIRINOX). CAPOX swaps the 5-FU infusion for capecitabine tablets.
FOLFOX or CAPOX for 3-6 months is adjuvant therapy for stage III colon cancer (IDEA showed 3 months suffices for low-risk disease); FOLFOX or FOLFIRI with an antibody (bevacizumab, or cetuximab/panitumumab for left-sided RAS wild-type) is first-line metastatic treatment, with FOLFOXIRI for fit patients needing maximal response. FOLFIRINOX (2011) and NALIRIFOX are the most active pancreatic regimens for fit patients, and FOLFOX is part of total neoadjuvant therapy for rectal cancer and of gastric and biliary regimens. Oxaliplatin causes cumulative cold-triggered neuropathy, irinotecan causes diarrhoea and neutropenia (UGT1A1-dependent).
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Showing the molecule this term concerns: Oxaliplatin.
Shares Irinotecan (and liposomal irinotecan), Oxaliplatin, Fluorouracil (5-FU), Colorectal cancer.
Shares Total neoadjuvant therapy (TNT, rectal cancer), Irinotecan (and liposomal irinotecan), Oxaliplatin, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation.
Shares Irinotecan (and liposomal irinotecan), Oxaliplatin, Fluorouracil (5-FU), Colorectal cancer.
Shares Irinotecan (and liposomal irinotecan), Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Fluorouracil (5-FU), Colorectal cancer.
Shares Peripheral neuropathy (chemotherapy-induced), Oxaliplatin, Fluorouracil (5-FU), Pancreatic ductal adenocarcinoma.
Shares Total neoadjuvant therapy (TNT, rectal cancer), Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Fluorouracil (5-FU), Colorectal cancer.
Shares Irinotecan (and liposomal irinotecan), Oxaliplatin, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Fluorouracil (5-FU).
Shares Irinotecan (and liposomal irinotecan), Oxaliplatin, Gastric & gastro-oesophageal junction cancer.